Search results
Clinical trial leads to FDA approved treatment for peripheral artery disease
MinnPost· 13 hours agoPeripheral artery disease or PAD, said Jennifer Jones-McMeans, Ph.D., divisional vice president of...
Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics
Investor's Business Daily· 1 day agoOn Friday, U.S. District Court Judge Richard Andrews denied United Therapeutics' request for a...
BrainsWay Receives Expanded FDA Labeling to Treat Late Life Depression - BrainsWay (NASDAQ:BWAY)
Benzinga· 2 days ago(NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the US Food ...
...from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and...
ThePress.net· 3 days agoInnovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the ...
Harrods, Las Vegas and here: Region part of vitamin IV trend
The Times-Tribune, Scranton, Pa. via Yahoo News· 1 day agoIt is a Kardashian favorite and a longstanding trend that you can join right here. IV vitamin drips at wellness businesses are enjoyed by many celebrities and< ...
Liquidia Rises 12% In Pre-market On Favorable Court Ruling For Yutrepia
RTT News· 2 days agoTherapeutics' request to block the launch of Liquidia's Yutrepia inhalation powder to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). "The ...
Study results indicate that pitavastatin inhibits interleukin-33 to suppress skin and pancreatic...
Medical Xpress· 6 days agoA new study led by investigators from Mass General Cancer Center reveals that statins—commonly used...
Gel-based male birth control is safe and effective, scientists report
Salon.com· 1 day ago“The development of a safe, highly effective and reliably reversible contraceptive method for men is an unmet need,” said senior researcher Diana Blithe, Ph
CARVYKTI® (ciltacabtagene autoleucel) significantly improved progression-free survival and deepened...
Valley City Times Record· 1 day agoJohnson & Johnson announced today results from a subgroup analysis of the Phase 3 CARTITUDE-4 study. Data from the CARTITUDE-4 study supported the recent U.S. FDA approval of CARVYKTI®, the ...
Small Business - Picayune Item | Picayune Item
The Picayune Item· 2 days agoThe launch comes after the recent clearance of the syndromic test for clinical use by the U.S. Food and Drug Administration& ...